Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.47 |
| ▸ | TUBB | P07437 | 7/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299183 | 0.88 | PTGS2 (0.65) | PTGS2MAPTCREBBPMEN1ALDH1A1 | |
| SCHEMBL299172 | 0.83 | PTGS2 (0.71) | PTGS2MAPTCREBBPMEN1ALDH1A1 | |
| SCHEMBL801290 | 0.82 | PDF (0.52) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL290051 | 0.82 | PDF (0.52) | PTGS2MAPTTUBB4ATUBBTUBA3C | |
| SCHEMBL28171359 | 0.81 | RAB9A (0.55) | MAPTRAB9AKMT2ATUBB4ATUBB | |
| SCHEMBL27843650 | 0.80 | MAPT (0.77) | PTGS2MAPTCREBBPMEN1ALDH1A1 | |
| SCHEMBL16994940 | 0.79 | PDF (0.49) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2127784 | 0.79 | TUBB1 (0.50) | MAPTMEN1ALDH1A1KMT2ATUBB4A | |
| SCHEMBL17997094 | 0.79 | TSHR (0.60) | PTGS2MAPTCREBBPMEN1ALDH1A1 | |
| SCHEMBL2128636 | 0.76 | TUBB1 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2959898-A1 | 4,5-DIOXO-NAPHTHO[1,2-b]FURANS AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2427057-B1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN KETTERING INST CANCER (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614237-B2 | Benzofuran-4,5-diones as selective peptide deformylase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2427057-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | Sloan-Kettering Institute for Cancer Research (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129049-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071523-A1 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS | PDF, EIF5B, EIF4E | PTGS2 2098/4885MAPT 3128/4885CREBBP 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.